The combination of MET with simvastatin decreased the survival of GBM by inducing a senescent phenotype, blocking the formation of spheres of GBM CSC, and modulating signaling pathways such as AKT or the TGFβ-pathway. Here, AKT1 is linked to glioblastoma.